Quantitative Measurement of Serum MicroRNA-21 Expression in Relation to Breast Cancer Metastasis in Chinese Females
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Breast cancer is the most common type of cancer in females. Aberrant expression of microRNA-21 (miR-21) has previously been reported in breast cancer tissue. The aim of this study was to investigate expression levels of serum miR-21 in breast cancer patients and evaluate its prognostic value in Chinese females. Methods: Real-time quantitative (RQ)-PCR was used to analyze miR-21 expression in archived serum, tumor tissue, and adjacent normal tissue from 549 participants (326 with breast cancer, 223 without breast cancer). We also analyzed associations between serum miR-21 expression and breast cancer subtypes and patient prognosis. Recurrence and survival were analyzed by using the multivariate Cox proportional hazards model. Results: Expression of miR-21 was significantly higher in breast cancer tissues compared with normal adjacent breast tissues (P<0.001). The 2-ΔΔCt values for serum miR-21 in breast cancer patients versus healthy controls were 9.12±3.43 and 2.96±0.73, respectively. Multivariate Cox proportional hazards model suggested that serum miR-21 expression was an independent poor prognostic factor for both recurrence (hazard ratio [HR]= 2.942; 95% confidence interval [CI]=1.420-8.325; P=0.008) and disease-free survival (HR=2.732; 95% CI=1.038-7.273, P=0.003) in breast cancer. Conclusions: Increased serum miR-21 expression level was correlated with poor prognosis of breast cancer patients, indicating that serum miR-21 may be a novel prognostic marker for recurrence and survival of breast cancer patients before resection.
Abstract
Background: Breast cancer is the most common type of cancer in females. Aberrant expression of microRNA-21 (miR-21) has previously been reported in breast cancer tissue. The aim of this study was to investigate expression levels of serum miR-21 in breast cancer patients and evaluate its prognostic value in Chinese females. Methods: Real-time quantitative (RQ)-PCR was used to analyze miR-21 expression in archived serum, tumor tissue, and adjacent normal tissue from 549 participants (326 with breast cancer, 223 without breast cancer). We also analyzed associations between serum miR-21 expression and breast cancer subtypes and patient prognosis. Recurrence and survival were analyzed by using the multivariate Cox proportional hazards model. Results: Expression of miR-21 was significantly higher in breast cancer tissues compared with normal adjacent breast tissues (P<0.001). The 2-ΔΔCt values for serum miR-21 in breast cancer patients versus healthy controls were 9.12±3.43 and 2.96±0.73, respectively. Multivariate Cox proportional hazards model suggested that serum miR-21 expression was an independent poor prognostic factor for both recurrence (hazard ratio [HR]= 2.942; 95% confidence interval [CI]=1.420-8.325; P=0.008) and disease-free survival (HR=2.732; 95% CI=1.038-7.273, P=0.003) in breast cancer. Conclusions: Increased serum miR-21 expression level was correlated with poor prognosis of breast cancer patients, indicating that serum miR-21 may be a novel prognostic marker for recurrence and survival of breast cancer patients before resection.
참고문헌 (27)
- Jemal A, "Global cancer statistics", CA Cancer J Clin, 61, pp.69~90 (2011)
- Wightman B, "Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans", Cell, 75, pp.855~862 (1993)
- Michael MZ, "Reduced accumulation of specific microRNAs in colorectal neoplasia", Mol Cancer Res, 1, pp.882~891 (2003)
- Calin GA, "Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers", Proc Natl Acad Sci USA, 101, pp.2999~3004 (2004)
- Wang F, "Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor", Gynecol Oncol, 119, pp.586~593 (2010)
- Cortez MA, "MicroRNAs in body fluids--the mix of hormones and biomarkers", Nat Rev Clin Oncol, 8, pp.467~477 (2011)
- Kishimoto T, "Plasma miR-21 is a novel diagnostic biomarker for biliary tract cancer", Cancer Sci, 104, pp.1626~1631 (2013)
- Zhao H, "A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer", PLos One, 5, pp.e13735~ (2010)
- Edge SB, "AJCC cancer staging manual" (2009), Springer-Verlag
- Asaga S, "Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer", Clin Chem, 57, pp.84~91 (2011)
- Mar-Aguilar F, "Serum circulating microRNA profiling for identification of potential breast cancer biomarkers", Dis Markers, 34, pp.163~169 (2013)
- Chan M, "Identification of circulating microRNA signatures for breast cancer detection", Clin Cancer Res, 19, pp.4477~4487 (2013)
- Iorio MV, "MicroRNA gene expression deregulation in human breast cancer", Cancer Res, 65, pp.7065~7070 (2005)
- Calin GA, "Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications", J Clin Invest, 117, pp.2059~2066 (2007)
- Qian B, "High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-ß1", Breast Cancer Res Treat, 117, pp.131~140 (2009)
- Yan LX, "Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth", Breast Cancer Res, 13, pp.R2~ (2011)
- Kumar S, "Overexpression of circulating miRNA-21 and miRNA-146a in plasma samples of breast cancer patients", Indian J Biochem Biophys, 50, pp.210~214 (2013)
- Gao J, "Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA", Chin J Cancer Res, 25, pp.743~748 (2013)
- Müller V, "Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial", Breast Cancer Res Treat, 147, pp.61~68 (2014)
- Tamaki K, "Analysis of clinically relevant values of Ki-67 labeling index in Japanese breast cancer patients", Breast Cancer, 21, pp.325~333 (2014)
- Leivonen SK, "Protein lysate microarry analysis to identify microRNAs regulating estrogen receptor signaling in braest cancer cell lines", Oncogene, 28, pp.3926~3936 (2009)
- Fackenthal JD, "Breast cancer risk associated with BRCA1and BRCA2 in diverse populations", Nat Rev Cancer, 7, pp.937~948 (2007)
- Si ML, "miR-21-mediated tumor growth", Oncogene, 26, pp.2799~2803 (2007)
- Li J, "MicroRNAs in breast cancer and breast cancer stem cells and their potential for breast cancer therapy", Chin Med J, 126, pp.2556~2563 (2013)
- Tsujiura M, "Circulating microRNAs in plasma of patients with gastric cancers", Br J Cancer, 102, pp.1174~1179 (2010)
- Wu Q, "Analysis of serum genome-wide microRNAs for breast cancer detection", Clin Chim Acta, 413, pp.1058~1065 (2012)
- Fu SW, "miRNA biomarkers in breast cancer detection and management", J Cancer, 2, pp.116~122 (2011)